In-/Exclusion criteria
INFORM

INdividualized Therapy FOr Relapsed Malignancies in Childhood

Coordinating Investigator Registry: Prof. Dr. med. Olaf Witt

NCT Clinical Trial Center Heidelberg
Cornelis van Tilburg / Ruth Witt
Tel: 06221-56-7255
Email: INFORM_info@DKFZ.de

Version and date: Version 5.0, dated 05.07.2016
General inclusion criteria:

- Children, adolescents and young adults 1 to 40 years old with refractory/relapsed/progressive oncological disease following first, second or third line treatment protocols (except for specific primary soft tissue sarcomas, primary diffuse intrinsic pontine glioma and “other” refractory or progressive/relapsed entities including rare tumor diseases), including targeted treatment approaches considering entity-specific high risk criteria

- Patients can be included up until the age of 40 years, but they must have had their primary diagnosis below the age of 21 years

- No established curative treatment options

- Life expectancy > 3 months and sufficient general condition (Lansky ≥ 50 or Karnofsky ≥ 50)

- First-line treatment within one of the therapy optimization/registry trials of the GPOH or an equivalent protocol, except for specific primary soft tissue sarcomas, primary diffuse intrinsic pontine glioma and “other” refractory or progressive/relapsed entities including rare tumor diseases

- Residency in Germany or in one of the partner countries

- Inclusion in INFORM Registry discussed with and agreed by respective GPOH Entity Study group (or with the respective national coordinator)

- Histopathological/molecular confirmation of clinically suspected diagnosis

- Solid tumors: present measurable disease activity (residual mass/metastasis) after biopsy/puncture

- Routine biopsy/puncture of the current refractory/relapsed/progressive oncological disease as part of standard of care treatment
• Time between biopsy/puncture of the current refractory/relapsed/progressive oncological disease and receipt of all required samples in the Central Pathology Laboratory in Heidelberg < 8 weeks

• Solid tumors: Fresh frozen (FF), tumor of the current refractory/relapsed/progressive disease and non-malignant material will be sent to INFORM Registry for molecular analysis

• Leukemias: Fresh frozen leukemic blasts or prepared DNA/RNA of the current refractory/relapsed/progressive disease and non-malignant material sent to INFORM Registry for molecular analysis

• Written informed consent of the patients and/or the legal guardians concerning data and tumor material transfer

**Entity specific in-/exclusion criteria:**

**ALL-HR**
Inclusion Criteria:
• Refractory disease at first relapse (> 40% blasts in bone marrow)
• At least 2nd relapse post Ctx (>40% blasts in bone marrow)
• Bone marrow involvement

**ALL post-SCT**
Inclusion Criteria
• Bone marrow relapse of ALL (> 40% blasts in bone marrow)
• Post allogeneic hematopoietic stem cell transplantation

**AML**
Inclusion Criteria:
• Early 1st relapse AML/ refractory disease following re-induction, 
  or at least 2nd relapse AML (>40% blasts in bone marrow or sorted blasts)

Exclusion Criteria:
• Acute promyelocytic leukemia
- Acute myeloid leukemia in patients with Down Syndrome

**Soft tissue sarcoma**

Inclusion Criteria:
- Combined or metastatic relapsed RMS,
  - or first-line therapy: Progressive RMS, no option for local therapy,
  - or primary metastatic RMS in patients age > 10 years or bone/bone marrow metastasis,
  - or non-resectable desmoplastic small round cell tumor (primary diagnosis or refractory/relapsed/progressive DSRCT)
- Other sarcomas

**Ependymoma and medulloblastoma**

Inclusion Criteria:
- Medulloblastoma or ependymoma (WHO°II or III)
- Refractory or progressive disease following first-line therapy or first or multiple relapse

**Ewing sarcoma**

Inclusion Criteria:
- Any relapsed and/or therapy refractory ewing sarcoma, including pPNET.
- Tumor at biopsy accessible site

**High grade glioma (incl. diffuse intrinsic pontine glioma)**

Inclusion Criteria:
- Diagnosis of relapsed/progressive high-grade malignant glioma (WHO grade 3 or 4 or analogous tumors) after first-line therapy
- Primary diffuse intrinsic pontine glioma

**Neuroblastoma**

Inclusion Criteria:
- High risk neuroblastoma patients; Any neuroblastoma relapse after high risk therapy,
  - or intermediate risk neuroblastoma patients: At least second relapse after HD chemotherapy and ASCT
- Relapsed tumor accessible to low risk surgery or, in case of bone marrow infiltration and only if tumor tissue not available, aspirate containing at least 40% neuroblast infiltration (% after cytospin, not in bone marrow smear)
NHL
Inclusion Criteria:
- Burkitt lymphoma, mature aggressive B-cell NHL not further classified or LBL with non-response, progression, or relapse

Osteosarcoma
Inclusion Criteria:
- Relapsed or first-line therapy refractory Osteosarcoma

Rhabdoid tumors
Inclusion Criteria:
- Relapse or first-line therapy refractory rhabdoid tumors

“Other” refractory or progressive/relapsed entities including rare tumor diseases
- Exceptional cases discussed with and agreed by INFORM Registry Trial Office, and in case of rare tumor diseases with the GPOH STEP registry